Lanette Smith, MD
Payments from drug & device makers
Across 48 payments — averaging $30.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vector Surgical, LLC$300
- Merck$183
- Bard Peripheral Vascular, Inc.$113
- Novartis$84
- Johnson & Johnson$69
- Sobi, Inc$64
- plus $650 from 22 others
What the payments were for
- Food & beverage$1,464100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vector Surgical, LLC | 1 | $300 |
| Merck | 7 | $183 |
| Bard Peripheral Vascular, Inc. | 1 | $113 |
| Novartis | 4 | $84 |
| Johnson & Johnson | 3 | $69 |
| Sobi, Inc | 2 | $64 |
| Genmab U.S., Inc. | 2 | $56 |
| Lilly USA, LLC | 2 | $50 |
| Stemline Therapeutics Inc. | 2 | $49 |
| Springworks Therapeutics, Inc. | 2 | $47 |
| AstraZeneca | 2 | $43 |
| Incyte Corporation | 2 | $37 |
| EMD Serono, Inc. | 2 | $37 |
| Bayer | 2 | $34 |
| Gilead | 1 | $30 |
| Beone Medicines USA, Inc. | 1 | $30 |
| AbbVie | 1 | $26 |
| Sanofi | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Adaptive Biotechnologies Corporation | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Pharmaessentia USA Corporation | 1 | $16 |
| Pharmaand GmbH | 1 | $15 |
| Tolmar, Inc. | 1 | $15 |
| Legend Biotech USA Inc. | 1 | $15 |
How this compares
$1,464 in reported general payments places this provider in the 55th percentile of 290 surgery providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 88 | $371 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $132 |
| Alprazolam | 20 | $22 |
Paid to pharmacies, not to this prescriber.
Other surgery in Tulsa
- Craig JohnsonTulsa$573K
- Eugene DickensTulsa$456K
- William JenningsTulsa$412K
- Bryce MurrayTulsa$152K
- Jared LepleyTulsa$93K
- Steven FeherTulsa$50K
- Samuel PangburnTulsa$50K
- Ty KirkpatrickTulsa$28K
- John KingTulsa$24K
- Michael ThomasTulsa$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.